Previous close | 6.22 |
Open | 6.38 |
Bid | 6.15 x 200 |
Ask | 6.25 x 100 |
Day's range | 6.12 - 6.40 |
52-week range | 5.75 - 14.50 |
Volume | |
Avg. volume | 315,834 |
Market cap | 296.367M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 22.00 |
BURLINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced that Dr. Harith Rajagopalan, CEO of Fractyl Health, will participate in a fireside chat at the upcoming BofA Securities 2024 Health Care Conference on Wednesday, May 15, 2024, at 4:20 p.m. PDT (7:20 p.m. EDT). To register in advance for the fireside cha
BURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced it will report financial results for the first quarter 2024 and provide business updates after market close on Monday, May 13, 2024. The Company’s management will host a conference call on the same day beginning at 4:30 p.m. ET. A live webcast of the co
Key Insights The considerable ownership by private equity firms in Fractyl Health indicates that they collectively have...